Forecasting the potential impact of cell and gene therapies in France: projecting product launches and patients treated
ObjectiveTo evaluate the potential impact of cell and gene therapies (CGTs) in France by forecasting the number of patients that will be treated with CGTs over the period 2023–2030 by therapeutic area and region.MethodsA review of CGTs in clinical development and related disease epidemiology was con...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1324602/full |
| _version_ | 1827347552845955072 |
|---|---|
| author | Ming Kei Lee Sama Seyedmousavi Sylvain Auvity Sylvain Auvity Bertrand Pourroy Vincent Elleboode Isabelle Kachaner Christel Jansen Herve Lilliu |
| author_facet | Ming Kei Lee Sama Seyedmousavi Sylvain Auvity Sylvain Auvity Bertrand Pourroy Vincent Elleboode Isabelle Kachaner Christel Jansen Herve Lilliu |
| author_sort | Ming Kei Lee |
| collection | DOAJ |
| description | ObjectiveTo evaluate the potential impact of cell and gene therapies (CGTs) in France by forecasting the number of patients that will be treated with CGTs over the period 2023–2030 by therapeutic area and region.MethodsA review of CGTs in clinical development and related disease epidemiology was conducted to forecast the number of CGT launches and patient population between 2023 and 2030. The number of expected launches was identified by filtering the clinical development pipeline with estimated time to launch and probability of success values from Project ALPHA. Disease prevalence and incidence in France were combined with projected adoption rates derived from historical data to forecast the patient population to be treated.ResultsUp to 44 new CGTs are forecasted to launch in France in the period 2023–2030, which translates into more than 69,400 newly treated patients in 2030. Leading indications in terms of newly treated patients per year include cardiovascular disease, hematological cancers and solid tumors with 27,300, 15,200 and 13,000 newly treated patients in 2030, respectively.DiscussionThe forecast suggests that the future landscape of CGTs will undergo a shift, moving from CGTs targeting (ultra) rare diseases to more prevalent diseases. In France, this will likely pose organizational challenges hindering patient access to these transformative therapies. Further research and planning around network organization and patient distribution are needed to assess and improve the readiness of the French healthcare system for ensuring access for this growing number of patients to be treated with CGTs. |
| first_indexed | 2024-03-07T23:52:20Z |
| format | Article |
| id | doaj.art-bb8bd8683d894df29fa28cd445fdebd0 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-03-07T23:52:20Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-bb8bd8683d894df29fa28cd445fdebd02024-02-19T04:29:15ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2024-02-011110.3389/fmed.2024.13246021324602Forecasting the potential impact of cell and gene therapies in France: projecting product launches and patients treatedMing Kei Lee0Sama Seyedmousavi1Sylvain Auvity2Sylvain Auvity3Bertrand Pourroy4Vincent Elleboode5Isabelle Kachaner6Christel Jansen7Herve Lilliu8Inbeeo, London, United KingdomInbeeo, London, United KingdomUniversité Paris Cité, INSERM, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Paris, FranceService de Pharmacie, AP-HP, Hôpital Necker, Paris, FranceOncopharma Unit, Pharmacy Department, University Teaching Hospital la Timone, Marseille, FrancePfizer Holding France, Paris, FrancePfizer Holding France, Paris, FranceInbeeo, London, United KingdomInbeeo, London, United KingdomObjectiveTo evaluate the potential impact of cell and gene therapies (CGTs) in France by forecasting the number of patients that will be treated with CGTs over the period 2023–2030 by therapeutic area and region.MethodsA review of CGTs in clinical development and related disease epidemiology was conducted to forecast the number of CGT launches and patient population between 2023 and 2030. The number of expected launches was identified by filtering the clinical development pipeline with estimated time to launch and probability of success values from Project ALPHA. Disease prevalence and incidence in France were combined with projected adoption rates derived from historical data to forecast the patient population to be treated.ResultsUp to 44 new CGTs are forecasted to launch in France in the period 2023–2030, which translates into more than 69,400 newly treated patients in 2030. Leading indications in terms of newly treated patients per year include cardiovascular disease, hematological cancers and solid tumors with 27,300, 15,200 and 13,000 newly treated patients in 2030, respectively.DiscussionThe forecast suggests that the future landscape of CGTs will undergo a shift, moving from CGTs targeting (ultra) rare diseases to more prevalent diseases. In France, this will likely pose organizational challenges hindering patient access to these transformative therapies. Further research and planning around network organization and patient distribution are needed to assess and improve the readiness of the French healthcare system for ensuring access for this growing number of patients to be treated with CGTs.https://www.frontiersin.org/articles/10.3389/fmed.2024.1324602/fullcell and gene therapiespatient forecast modelpharmaceutical development pipelineFrench healthcare systempatient accesshealthcare organization and delivery |
| spellingShingle | Ming Kei Lee Sama Seyedmousavi Sylvain Auvity Sylvain Auvity Bertrand Pourroy Vincent Elleboode Isabelle Kachaner Christel Jansen Herve Lilliu Forecasting the potential impact of cell and gene therapies in France: projecting product launches and patients treated Frontiers in Medicine cell and gene therapies patient forecast model pharmaceutical development pipeline French healthcare system patient access healthcare organization and delivery |
| title | Forecasting the potential impact of cell and gene therapies in France: projecting product launches and patients treated |
| title_full | Forecasting the potential impact of cell and gene therapies in France: projecting product launches and patients treated |
| title_fullStr | Forecasting the potential impact of cell and gene therapies in France: projecting product launches and patients treated |
| title_full_unstemmed | Forecasting the potential impact of cell and gene therapies in France: projecting product launches and patients treated |
| title_short | Forecasting the potential impact of cell and gene therapies in France: projecting product launches and patients treated |
| title_sort | forecasting the potential impact of cell and gene therapies in france projecting product launches and patients treated |
| topic | cell and gene therapies patient forecast model pharmaceutical development pipeline French healthcare system patient access healthcare organization and delivery |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1324602/full |
| work_keys_str_mv | AT mingkeilee forecastingthepotentialimpactofcellandgenetherapiesinfranceprojectingproductlaunchesandpatientstreated AT samaseyedmousavi forecastingthepotentialimpactofcellandgenetherapiesinfranceprojectingproductlaunchesandpatientstreated AT sylvainauvity forecastingthepotentialimpactofcellandgenetherapiesinfranceprojectingproductlaunchesandpatientstreated AT sylvainauvity forecastingthepotentialimpactofcellandgenetherapiesinfranceprojectingproductlaunchesandpatientstreated AT bertrandpourroy forecastingthepotentialimpactofcellandgenetherapiesinfranceprojectingproductlaunchesandpatientstreated AT vincentelleboode forecastingthepotentialimpactofcellandgenetherapiesinfranceprojectingproductlaunchesandpatientstreated AT isabellekachaner forecastingthepotentialimpactofcellandgenetherapiesinfranceprojectingproductlaunchesandpatientstreated AT christeljansen forecastingthepotentialimpactofcellandgenetherapiesinfranceprojectingproductlaunchesandpatientstreated AT hervelilliu forecastingthepotentialimpactofcellandgenetherapiesinfranceprojectingproductlaunchesandpatientstreated |